Author

Daniel Pouliquen

Centre National de la Recherche ScientifiqueORCID 0000-0002-0820-3828Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:metagenomics· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Aleksandr BarinoviD· 1 shared Anastassia V. KomarovaiD· 1 shared Atousa Arbabian· 1 shared Bernadette Brzezicha· 1 shared Chantal CombredetiD· 1 shared David HardyiD· 1 shared Eddy Simard· 1 shared Etienne Simon‐LorièreiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Aleksandr BarinovORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I-driven cancer immunotherapy

Aleksandr Barinov, Heidy Vera-Peralta, Joëlle S. Nader, Valérie Najburg, Chantal Combredet, Atousa Arbabian, Ségolène Gracias, Phanramphoei Namprachan Frantz, Roseline Vibert, Eddy Simard, Marie Coateval, Daniel Pouliquen, Tacien Petithomme, Matthieu Prot, Etienne Simon‐Lorière, , Frédéric Tangy

This paper modifies a measles vaccine by removing a viral protein to create a cancer immunotherapy that activates the immune system via RIG-I signaling, leading to tumor regression in multiple models.

bioRxiv · Oct 3, 2025 · PreprintImmunology